Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Matt Walz
Advertisement
The CEO of Trialbee. Walz brings more than 20 years of software and leadership experience in the life sciences industry. He started his career as a developer and held various technical and leadership roles at Rollins Corporation, PSCI, Microsoft, Morgan Lewis, and Datalabs. In 2006, Walz co-founded NextDocs, which grew to be a global leader in clinical, quality, and regulatory document management, where he served as CTO, CSO, and board director for nine years. Before joining Trialbee, Walz spent five years as general manager for life sciences and VP of strategic accounts for Aurea Software, which had acquired NextDocs.
Articles by Matt Walz
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
2
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
3
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
4
Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera
5